314 related articles for article (PubMed ID: 14698135)
1. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.
Pusztai L; Mendoza TR; Reuben JM; Martinez MM; Willey JS; Lara J; Syed A; Fritsche HA; Bruera E; Booser D; Valero V; Arun B; Ibrahim N; Rivera E; Royce M; Cleeland CS; Hortobagyi GN
Cytokine; 2004 Feb; 25(3):94-102. PubMed ID: 14698135
[TBL] [Abstract][Full Text] [Related]
2. Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer.
Qi M; Li JF; Xie YT; Lu AP; Lin BY; Ouyang T
Breast Cancer Res Treat; 2010 Aug; 123(1):197-202. PubMed ID: 20582466
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
4. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
Yu TK; Whitman GJ; Thames HD; Buzdar AU; Strom EA; Perkins GH; Schechter NR; McNeese MD; Kau SW; Thomas ES; Hortobagyi GN; Buchholz TA
J Natl Cancer Inst; 2004 Nov; 96(22):1676-81. PubMed ID: 15547180
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pigmentary side effects of taxanes and anthracyclines: an onychoscopic evaluation.
Yorulmaz A; Dogan M; Artuz F; Zengin N
Cutan Ocul Toxicol; 2017 Jun; 36(2):135-139. PubMed ID: 27086693
[TBL] [Abstract][Full Text] [Related]
6. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study of comparison of CAF regimen and TP regimen in treatment of advanced breast cancer].
Lin XG; Xie DR; Yao HR; Li ZH; Jiang ZM; Liu TH
Ai Zheng; 2003 Apr; 22(4):411-4. PubMed ID: 12704001
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Buzdar AU; Singletary SE; Valero V; Booser DJ; Ibrahim NK; Rahman Z; Theriault RL; Walters R; Rivera E; Smith TL; Holmes FA; Hoy E; Frye DK; Manuel N; Kau SW; McNeese MD; Strom E; Thomas E; Hunt K; Ames F; Berry D; Hortobagyi GN
Clin Cancer Res; 2002 May; 8(5):1073-9. PubMed ID: 12006521
[TBL] [Abstract][Full Text] [Related]
9. Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer.
Mantovani G; Macciò A; Lai P; Massa E; Massa D; Mulas C; Succu G; Mudu MC; Manca G; Versace R; Pisano A
J Immunother; 2000; 23(2):267-74. PubMed ID: 10746553
[TBL] [Abstract][Full Text] [Related]
10. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
Klaassen U; Wilke H; Seeber S
J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
[TBL] [Abstract][Full Text] [Related]
11. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
Green MC; Buzdar AU; Smith T; Ibrahim NK; Valero V; Rosales MF; Cristofanilli M; Booser DJ; Pusztai L; Rivera E; Theriault RL; Carter C; Frye D; Hunt KK; Symmans WF; Strom EA; Sahin AA; Sikov W; Hortobagyi GN
J Clin Oncol; 2005 Sep; 23(25):5983-92. PubMed ID: 16087943
[TBL] [Abstract][Full Text] [Related]
12. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer.
Geinitz H; Zimmermann FB; Stoll P; Thamm R; Kaffenberger W; Ansorg K; Keller M; Busch R; van Beuningen D; Molls M
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):691-8. PubMed ID: 11597810
[TBL] [Abstract][Full Text] [Related]
13. Resistance training does not protect against increases in plasma cytokine levels among germ cell cancer patients during and after chemotherapy.
Christensen JF; Tolver A; Andersen JL; Rørth M; Daugaard G; Hojman P
J Clin Endocrinol Metab; 2014 Aug; 99(8):2967-76. PubMed ID: 25050898
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
Spigel DR; Hainsworth JD; Burris HA; Molthrop DC; Peacock N; Kommor M; Vazquez ER; Greco FA; Yardley DA
Clin Adv Hematol Oncol; 2011 Apr; 9(4):280-6. PubMed ID: 21558987
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
Buzdar AU; Singletary SE; Theriault RL; Booser DJ; Valero V; Ibrahim N; Smith TL; Asmar L; Frye D; Manuel N; Kau SW; McNeese M; Strom E; Hunt K; Ames F; Hortobagyi GN
J Clin Oncol; 1999 Nov; 17(11):3412-7. PubMed ID: 10550135
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilatation.
Vassilakopoulou M; Mountzios G; Papamechael C; Protogerou AD; Aznaouridis K; Katsichti P; Venetsanou K; Dimopoulos MA; Ikonomidis I; Papadimitriou CA
Vascul Pharmacol; 2010; 53(3-4):115-21. PubMed ID: 20470900
[TBL] [Abstract][Full Text] [Related]
17. Failure of neutrophil chemotactic function in breast cancer patients treated with chemotherapy.
Mendonça MA; Cunha FQ; Murta EF; Tavares-Murta BM
Cancer Chemother Pharmacol; 2006 May; 57(5):663-70. PubMed ID: 16133528
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
